Contact Us

Consumer Services or Programs

If your question is about a medical condition, then you should consult with a healthcare professional or, in the case of an emergency, call 911 immediately.

Standard business hours for CSL Behring are 8:30 am to 5:00 pm eastern time.

CSL Behring Headquarters
Phone:	610-878-4000
Fax:	610-878-4009
Location:	North America Headquarters
Address:	P.O. Box 61501 1020 First Avenue King of Prussia, PA 19406 USA

Consumer Affairs
For Consumer Information
Phone:	888-508-6978
Fax:	610-878-4008

Medical Affairs
Phone:	800-504-5434
Fax:	610-878-4007

Adverse Events
Phone:	610-878-4193
Phone (After Business Hours): 866-915-6958

All fields marked with an asterisk (*) are required.

*To ensure that your question or comment is directed to the appropriate CSL Behring department, please select one of these choices:
* Salutation:
* First Name:
* Last Name:
* I Am a:

* Phone Number:
* E-mail Address:
* Confirm E-mail Address:
Please enter your comments:

*Type in the verification word in the box below (case sensitive):

Prior to submitting your information, please review our Privacy Policy.

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.